SCHEMBL22864231

SCHEMBL22864231

CC(C)(C)NC[C@@H](O)c1cccc2cccnc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 4/20 0.52
CYP2D6 P10635 4/20 0.52
ADRB2 P07550 3/20 0.52
ADRB1 P08588 2/20 0.52
NFKB1 P19838 1/20 0.52
BLM P54132 1/20 0.51
CYP2C19 P33261 2/20 0.41
LMNA P02545 3/20 0.41
TSHR P16473 2/20 0.40
MMP2 P08253 1/20 0.40
CHRM1 P11229 1/20 0.40
COMT P21964 1/20 0.40
ADRA1A P35348 1/20 0.40
METAP2 P50579 1/20 0.40
METAP1 P53582 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
PSMD14 O00487 1/20 0.40
COPS5 Q92905 1/20 0.40
CYP3A4 P08684 2/20 0.39
CYP2C9 P11712 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24630971 1.00 HIF1A (0.52) HIF1ACYP2D6ADRB2ADRB1NFKB1
SCHEMBL24631054 0.84 ADRB2 (0.45) HIF1ACYP2D6ADRB2ADRB1NFKB1
SCHEMBL24630968 0.83 ADRB2 (0.50) HIF1ACYP2D6ADRB2ADRB1NFKB1
SCHEMBL24631013 0.83 ADRB2 (0.52) HIF1ACYP2D6ADRB2ADRB1NFKB1
SCHEMBL24630960 0.83 ADRB2 (0.52) HIF1ACYP2D6ADRB2ADRB1NFKB1
SCHEMBL24631012 0.82 ADRB2 (0.48) HIF1ACYP2D6ADRB2ADRB1NFKB1
SCHEMBL22864225 0.82 HIF1A (0.51) HIF1ACYP2D6ADRB2ADRB1NFKB1
SCHEMBL24630910 0.82 HIF1A (0.51) HIF1ACYP2D6ADRB2ADRB1NFKB1
SCHEMBL22481180 0.81 HIF1A (0.56) HIF1ACYP2D6ADRB2ADRB1NFKB1
SCHEMBL22493460 0.81 HIF1A (0.56) HIF1ACYP2D6ADRB2ADRB1NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220315534-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. 2022-10-06 US disclosed
WO-2021003161-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2021-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315534-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME ADRB2, ADRB1, ADRA2C HIF1A 2371/4885CYP2D6 946/4885ADRB2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.